bluebird bio

Bluebird bio is a biotechnology company headquartered in Somerville, Massachusetts. The company employs 13 people and generates an annual revenue of $100 million. Founded in 2010, Bluebird bio is dedicated to developing curative gene therapies for patients with severe genetic diseases. The company focuses on treating sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, with industry-leading programs for these conditions. Bluebird bio custom designs each therapy to address the root cause of the disease and has developed advanced analytical methods to ensure the safety of its lentiviral vector technologies. Bluebird bio possesses the world’s largest and most extensive ex-vivo gene therapy dataset, setting a benchmark for the industry. This experience, combined with a patient-centric culture, attracts and nurtures a dedicated team of professionals. For more information about Bluebird bio and its commitment to advancing gene therapy, please visit their website at bluebirdbio.com.